We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-15.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.91B
AUM Growth
-$2.06B
Cap. Flow
+$62M
Cap. Flow %
0.63%
Top 10 Hldgs %
40.04%
Holding
153
New
17
Increased
26
Reduced
29
Closed
21

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$123M
2
WMGI
Wright Medical Group Inc
WMGI
+$120M
3
LLY icon
Eli Lilly
LLY
+$107M
4
HCA icon
HCA Healthcare
HCA
+$72.7M
5
DVAX
Dynavax Technologies
DVAX
+$70M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$161M
2
SHPG
Shire pic
SHPG
+$153M
3
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$120M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$119M
5
GILD icon
Gilead Sciences
GILD
+$79M

Sector Composition

Rank Sector Weight
1 Healthcare 92.06%
2 Financials 0.24%
3 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYNA
76
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$18.4M 0.19%
1,140,325
– –
SYK icon
77
Stryker
SYK
$134B
$17.5M 0.18%
186,000
– –
EHTH icon
78
eHealth
EHTH
$43.5M
$16.7M 0.17%
1,300,000
– –
JAZZ icon
79
Jazz Pharmaceuticals
JAZZ
$16.2B
$15.3M 0.15%
115,000
– –
HNT
80
CALL
DELISTED
HEALTH NET INC
HNT
$15.1M 0.15%
+250,000
New +$16.6M
NTRA icon
81
Natera
NTRA
$36B
$13.8M 0.14%
+1,276,190
New +$21.6M
XNCR icon
82
Xencor
XNCR
$1.47B
$13.8M 0.14%
1,130,022
+85,407
+8% +$1.67M
SVA
83
DELISTED
Sinovac Biotech, Ltd
SVA
$13.6M 0.14%
2,667,500
– –
ASMB icon
84
Assembly Biosciences
ASMB
$507M
$13.4M 0.13%
116,425
– –
PVLA
85
Palvella Therapeutics
PVLA
$2.05B
$13.3M 0.13%
90,745
– –
NBRV
86
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$12.5M 0.13%
+5,260
New +$13.9M
SGYP
87
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$12.1M 0.12%
2,276,648
-844,500
-27% -$6.54M
VRTX icon
88
Vertex Pharmaceuticals
VRTX
$125B
$12M 0.12%
115,000
– –
CAH icon
89
Cardinal Health
CAH
$54.3B
$11.2M 0.11%
146,000
– –
ENSG icon
90
The Ensign Group
ENSG
$10.7B
$10.6M 0.11%
529,369
– –
BAX icon
91
Baxter International
BAX
$12.8B
$10.5M 0.11%
+319,000
New +$12.1M
WCG
92
DELISTED
Wellcare Health Plans, Inc.
WCG
$9.82M 0.1%
+114,000
New +$9.99M
CLLS
93
Cellectis
CLLS
$283M
$9.23M 0.09%
350,000
– –
BXLT
94
DELISTED
BAXALTA INC COM STK (DE)
BXLT
$8.98M 0.09%
+285,000
New +$9.83M
ABT icon
95
Abbott
ABT
$190B
$8.49M 0.09%
211,000
– –
MRTX
96
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.26M 0.08%
240,000
-440,500
-65% -$13.3M
CNXR
97
DELISTED
Connecture, Inc.
CNXR
$7.93M 0.08%
1,740,000
– –
AET
98
DELISTED
Aetna Inc
AET
$7.33M 0.07%
67,000
-29,000
-30% -$3.35M
MCRB icon
99
Seres Therapeutics
MCRB
$45.8M
$7.31M 0.07%
12,332
– –
RDHL
100
Redhill Biopharma
RDHL
$4.26M
$7.29M 0.07%
565
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2015 Portfolio in Review

As of Q3 2015, OrbiMed held 153 positions worth $9.91B, down 17% from $12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q3 2015 filing shows 17 new, 26 increased, 29 reduced and 21 closed positions. Its largest new stake was Eli Lilly: 1,272,000 shares worth $106M. The largest sale was MEDIVATION, INC., an estimated $161M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 87% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q3 2015 buy was Eli Lilly: 1,272,000 shares worth $106M.
  • OrbiMed added most to Teva Pharmaceuticals in Q3 2015, an estimated $123M increase.
  • OrbiMed's biggest Q3 2015 reduction was Shire pic, cutting an estimated $153M.
  • OrbiMed fully exited MEDIVATION, INC. in Q3 2015, selling an estimated $161M.
  • OrbiMed's ten largest holdings make up 40% of its $9.91B portfolio in Q3 2015.
  • OrbiMed opened 17 new positions and closed 21 in Q3 2015.
  • OrbiMed's portfolio value fell 17% quarter-over-quarter to $9.91B.

Based on OrbiMed's 13F filing for Q3 2015, filed 13 Nov 2015.